# Pfizer Inc. – Consensus ‘buy’ rating and 26.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/pfizer-inc.consensus-buy-rating-and-26.5-upside-potential/4121131798
- Published: 2023-11-01T13:56:36+00:00
- Author: Charlotte Edwards

**Pfizer Inc.** which can be found using ticker (PFE) have now 21 market analysts
covering the stock. The analyst consensus now points to a rating of ‘buy’. The target
price High/Low ranges between $70.73 and $30.18 and has a mean target at $38.67.
Given that the stocks previous close was at $30.56 this indicates there is a potential
upside of 26.5%. The day 50 moving average is $33.39 and the 200 moving average 
now moves to $37.92. The market cap for the company is 174.32B. The stock price 
is currently at: $30.88 USD

 The potential market cap would be $220,579,736,329 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 8.21, revenue per share of $13.86
and a 7.63% return on assets.

Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged
in the discovery, development, manufacture, marketing, sale and distribution of 
biopharmaceutical products around the world. The Company operates through two segments:
Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business.
PC1 is its global contract development and manufacturing organization and supplier
of specialty active pharmaceutical ingredients. The Company’s primary care products
include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, 
Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty
care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra,
Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin,
and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products
include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.

Share on: